CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionReturn on equity is -192.5%, lower than 95% of its Biotechnology peers (median 6.6%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
12.45BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
-1.24xvs all stocks
52-Week Change
-27.27%vs all stocks
Market Capitalization
12.45BUSDvs all stocks (USD)
Enterprise Value
11.78BUSDvs all stocks (USD)
Forward P/E
-13.31xvs Biotechnology peers
Price to Book (MRQ)
19.66xvs Biotechnology peers
Enterprise to EBITDA
-13.47xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-101.61%vs Biotechnology peers
Return on Equity (TTM)
-192.50%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 28, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-874.67MUSDvs all stocks (USD)
Net Income (TTM)
-856.09MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-458.43MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-139.68MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-1.09BUSDvs all stocks (USD)
Pre-tax Income
-1.08BUSDFY2025 · Dec 31, 2025Net Income
-1.08BUSDFY2025 · Dec 31, 2025EBIT
-1.08BUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-1.09BUSDFY2025 · Dec 31, 2025Research & Development
537.67MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
556.70MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
0.00USDFY2025 · Dec 31, 2025EPS (Basic)
-1.44USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.44USDFY2025 · Dec 31, 2025Basic Shares Outstanding
747.70MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
747.70MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-1.08BUSDFY2025 · Dec 31, 2025Operating Cash Flow
-336.31MUSDFY2025 · Dec 31, 2025Free Cash Flow
-336.97MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
225.58MUSDFY2025 · Dec 31, 2025Income Tax Paid
0.00USDFY2025 · Dec 31, 2025Interest Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-1.08BUSDFY2025 · Dec 31, 2025Depreciation & Amortization
146.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
732.42MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
15.30MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-4.59MUSDFY2025 · Dec 31, 2025Capital Expenditures
-657.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-484.99MUSDFY2025 · Dec 31, 2025Sale of Investments
311.34MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-174.31MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
604.57MUSDFY2025 · Dec 31, 2025Shares Outstanding
793.12MSharesUpdated Sep 28, 2026Float Shares
152.28MSharesUpdated Sep 28, 2026Shares Short
41.08MSharesUpdated Sep 28, 2026Short Ratio
6.44daysvs all stocks
Short % of Shares Outstanding
26.26%vs all stocks
% Held by Insiders
80.89%vs all stocks
% Held by Institutions
17.51%vs all stocks
Total Cash (MRQ)
690.68MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.8660USDUpdated Sep 28, 2026Total Debt (MRQ)
20.38MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0324xvs Biotechnology peers
Current Ratio (MRQ)
6.96xvs Biotechnology peers
Book Value per Share (MRQ)
0.7940USDUpdated Sep 28, 2026Total Assets
751.18MUSDvs all stocks (USD)
Total Current Assets
720.30MUSDFY2025 · Dec 31, 2025Total Liabilities
92.32MUSDFY2025 · Dec 31, 2025Total Non-current Assets
30.88MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
19.33MUSDFY2025 · Dec 31, 2025Total Current Liabilities
72.99MUSDFY2025 · Dec 31, 2025Cash
16.37MUSDFY2025 · Dec 31, 2025Cash Equivalents
208.90MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
225.27MUSDFY2025 · Dec 31, 2025Other Short-term Investments
488.18MUSDFY2025 · Dec 31, 2025Accounts Payable
20.29MUSDFY2025 · Dec 31, 2025Short-term Debt
3.39MUSDFY2025 · Dec 31, 2025Other Current Liabilities
2.28MUSDFY2025 · Dec 31, 2025Long-term Debt
17.50MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
1.83MUSDFY2025 · Dec 31, 2025Common Stock (Book)
7.75MUSDFY2025 · Dec 31, 2025Retained Earnings
-2.29BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
658.86MUSDvs all stocks (USD)
52-Week Low
12.07USDUpdated Sep 28, 202652-Week High
29.23USDUpdated Sep 28, 202652-Week Change
-27.27%vs all stocks
Beta
-1.24xvs all stocks
50-Day MA
14.82USDUpdated Sep 28, 2026200-Day MA
16.38USDUpdated Sep 28, 2026Avg 10-Day Volume
6.13MSharesUpdated Sep 28, 2026Avg 30-Day Volume
6.40MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-1.11USDUpdated Sep 28, 2026Other Income / Expense
14.84MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -192.5%, lower than 95% of its Biotechnology peers (median 6.6%)Significant
Return on equity: -1.93Industry median: 0.07Industry P5: -1.64Peers compared: 22.00
Return on assets is -101.6%, lower than 95% of its Biotechnology peers (median 5.1%)Significant
Return on assets: -1.02Industry median: 0.05Industry P5: -0.77Peers compared: 22.00
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 35,799,263.917
Market cap is $12.45B, above the global median of $1.15BNotable
Market cap (USD): 12,452,871,287Global Median: 1,150,342,212.262
Companies that share the same coordination system — how they create, deliver, or capture value.
Corcept Therapeutics Incorporated
Tier 1ProductionApproval-Gated PipelineRule
Penumbra Inc.
Tier 1ProductionApproval-Gated PipelineRule
ALTEOGEN Inc.
Tier 1ProductionApproval-Gated PipelineRule
Swedish Orphan Biovitrum AB
Tier 1ProductionApproval-Gated PipelineRuleRisk
BridgeBio Pharma, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang NHU Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Halozyme Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Madrigal Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cipla Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Biomarin Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRule